Cargando…

The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study

Non-small cell lung cancer (NSCLC) is still diagnosed at late stages in Brazil. The availability of newer treatment options has changed patient management, however, few real-world data have been published since then. This is a population-based retrospective cohort study that aims to evaluate the cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerqueira, Erica R., Batista, Paula M., Almeida, Milena F., Rego, Maria A. C., Ribeiro-Pereira, Ana C. P., Alencar, Fernando, Fernandes, Roberta A., Calabrich, Aknar F. C., Schvartsman, Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619689/
https://www.ncbi.nlm.nih.gov/pubmed/37920156
http://dx.doi.org/10.3389/fonc.2023.1257003
_version_ 1785130040691785728
author Cerqueira, Erica R.
Batista, Paula M.
Almeida, Milena F.
Rego, Maria A. C.
Ribeiro-Pereira, Ana C. P.
Alencar, Fernando
Fernandes, Roberta A.
Calabrich, Aknar F. C.
Schvartsman, Gustavo
author_facet Cerqueira, Erica R.
Batista, Paula M.
Almeida, Milena F.
Rego, Maria A. C.
Ribeiro-Pereira, Ana C. P.
Alencar, Fernando
Fernandes, Roberta A.
Calabrich, Aknar F. C.
Schvartsman, Gustavo
author_sort Cerqueira, Erica R.
collection PubMed
description Non-small cell lung cancer (NSCLC) is still diagnosed at late stages in Brazil. The availability of newer treatment options has changed patient management, however, few real-world data have been published since then. This is a population-based retrospective cohort study that aims to evaluate the characteristics of stage III/IV NSCLC patients and their journey in the Brazilian private healthcare system. Patients aged ≥18 years, residing in Brazil who had their first medical appointment between 2016 and 2018 were included in the study. The sociodemographic and clinical characteristics of the patients and time intervals of interest were described. A total of 10,394 patients were analyzed. The majority of the patients were male (58.5%) with a median age of 64.0 (IQR = 58.0 – 71.0) years. In relation to characteristics of the disease, most of the tumors were characterized as adenocarcinomas (52.3%) and diagnosed at stage IV (72.2%). Most patients arrived at the hospital with an established NSCLC diagnosis, while 45.7% were diagnosed at the first medical appointment in the hospital or later. For patients who were diagnosed at the first medical appointment or later, a median interval of 15.0 (IQR = 6.0 – 33.0) days was observed between the first medical appointment and the diagnosis. The first treatment was given after a median of 25.0 (IQR = 6.0 – 49.0) days after diagnosis for patients without a prior diagnosis, and 57.0 (IQR: 33.0 – 98.0) days for patients with a prior diagnosis. The most common treatments were chemotherapy alone (33.8%), chemotherapy combined with radiotherapy (21.5%), radiotherapy alone (13.1%), adjuvant or neoadjuvant treatment (9.3%), surgery (3.3%), and immunotherapy (0.7%; alone or combined). At the end of follow-up (September, 2020), 52.3% of the patients had died. Despite having more treatment options in the private sector, data show that there is a need to improve access to technologies.
format Online
Article
Text
id pubmed-10619689
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106196892023-11-02 The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study Cerqueira, Erica R. Batista, Paula M. Almeida, Milena F. Rego, Maria A. C. Ribeiro-Pereira, Ana C. P. Alencar, Fernando Fernandes, Roberta A. Calabrich, Aknar F. C. Schvartsman, Gustavo Front Oncol Oncology Non-small cell lung cancer (NSCLC) is still diagnosed at late stages in Brazil. The availability of newer treatment options has changed patient management, however, few real-world data have been published since then. This is a population-based retrospective cohort study that aims to evaluate the characteristics of stage III/IV NSCLC patients and their journey in the Brazilian private healthcare system. Patients aged ≥18 years, residing in Brazil who had their first medical appointment between 2016 and 2018 were included in the study. The sociodemographic and clinical characteristics of the patients and time intervals of interest were described. A total of 10,394 patients were analyzed. The majority of the patients were male (58.5%) with a median age of 64.0 (IQR = 58.0 – 71.0) years. In relation to characteristics of the disease, most of the tumors were characterized as adenocarcinomas (52.3%) and diagnosed at stage IV (72.2%). Most patients arrived at the hospital with an established NSCLC diagnosis, while 45.7% were diagnosed at the first medical appointment in the hospital or later. For patients who were diagnosed at the first medical appointment or later, a median interval of 15.0 (IQR = 6.0 – 33.0) days was observed between the first medical appointment and the diagnosis. The first treatment was given after a median of 25.0 (IQR = 6.0 – 49.0) days after diagnosis for patients without a prior diagnosis, and 57.0 (IQR: 33.0 – 98.0) days for patients with a prior diagnosis. The most common treatments were chemotherapy alone (33.8%), chemotherapy combined with radiotherapy (21.5%), radiotherapy alone (13.1%), adjuvant or neoadjuvant treatment (9.3%), surgery (3.3%), and immunotherapy (0.7%; alone or combined). At the end of follow-up (September, 2020), 52.3% of the patients had died. Despite having more treatment options in the private sector, data show that there is a need to improve access to technologies. Frontiers Media S.A. 2023-10-18 /pmc/articles/PMC10619689/ /pubmed/37920156 http://dx.doi.org/10.3389/fonc.2023.1257003 Text en Copyright © 2023 Cerqueira, Batista, Almeida, Rego, Ribeiro-Pereira, Alencar, Fernandes, Calabrich and Schvartsman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cerqueira, Erica R.
Batista, Paula M.
Almeida, Milena F.
Rego, Maria A. C.
Ribeiro-Pereira, Ana C. P.
Alencar, Fernando
Fernandes, Roberta A.
Calabrich, Aknar F. C.
Schvartsman, Gustavo
The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study
title The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study
title_full The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study
title_fullStr The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study
title_full_unstemmed The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study
title_short The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study
title_sort journey of stage iii and iv non-small cell lung cancer patients in the brazilian private healthcare system: a retrospective study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619689/
https://www.ncbi.nlm.nih.gov/pubmed/37920156
http://dx.doi.org/10.3389/fonc.2023.1257003
work_keys_str_mv AT cerqueiraericar thejourneyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT batistapaulam thejourneyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT almeidamilenaf thejourneyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT regomariaac thejourneyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT ribeiropereiraanacp thejourneyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT alencarfernando thejourneyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT fernandesrobertaa thejourneyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT calabrichaknarfc thejourneyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT schvartsmangustavo thejourneyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT cerqueiraericar journeyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT batistapaulam journeyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT almeidamilenaf journeyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT regomariaac journeyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT ribeiropereiraanacp journeyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT alencarfernando journeyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT fernandesrobertaa journeyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT calabrichaknarfc journeyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy
AT schvartsmangustavo journeyofstageiiiandivnonsmallcelllungcancerpatientsinthebrazilianprivatehealthcaresystemaretrospectivestudy